CAR-T cell therapy has emerged as a promising treatment for Non-Hodgkin Lymphoma (NHL), particularly for patients with chemotherapy-resistant forms of the disease. This article reviews the structure, molecular mechanisms, clinical trial results, and challenges of CAR-T cell-based therapies, focusing on their application in NHL.

Dana-Farber researchers have developed a groundbreaking PET imaging probe targeting CD45 that enables highly sensitive and selective detection of inflammation throughout the body. The technology shows promise for monitoring inflammatory diseases, cancer immunotherapy responses, and early detection of graft-versus-host disease, with clinical trials on the horizon.

Biogen announces regulatory acceptance of supplemental applications for a higher-dose regimen of Spinraza (nusinersen) for spinal muscular atrophy by both FDA and EMA. This development comes as the company implements strategic research unit restructuring, including workforce reductions, under new research head Jane Grogan to streamline drug development processes.

A new post-market validation study published in CHEST Pulmonary Journal confirms the effectiveness of Biodesix's Nodify CDT blood test for lung nodule assessment. The study of 447 patients demonstrated high specificity in identifying benign lung nodules, outperforming PET scans in reducing false positives and potentially unnecessary invasive procedures.

Keros Therapeutics has voluntarily suspended remaining dosing arms in the Phase 2 TROPOS trial of cibotercept for pulmonary arterial hypertension (PAH) due to multiple cases of pericardial effusion. The development has led to a stock price target reduction by BofA, though analysts maintain a Buy rating despite the setback.

Corvus Pharmaceuticals reported a net loss of $6.7 million for Q4 2023, with R&D expenses totaling $4 million. The company is preparing for Phase 3 trials of soquelitinib for PTCL and a Phase 1 trial for atopic dermatitis in 2024, highlighting significant market opportunities and clinical progress.

A study on the use of intra-arterial tenecteplase following endovascular thrombectomy in patients with acute basilar artery occlusion shows promising results, with improved functional outcomes and reduced mortality rates compared to standard care. The trial, conducted in China, highlights the potential benefits and limitations of this treatment approach.

Intensity Therapeutics receives positive market outlook as Alliance Global Partners initiates coverage with a Buy rating, highlighting the potential of their lead compound INT230-6. The drug's dual mechanism of action targets tumor reduction while enhancing immune response in advanced soft tissue sarcoma and triple negative breast cancer patients.

Harvard Apparatus Regenerative Technology, Inc. (HRGN) has received $5 million in funding through a private placement to advance clinical trials of its HRGN Esophageal Implant (BEI).

KT-474, a novel small molecule, selectively inhibits MyD88, a key signaling protein in inflammatory pathways, offering a potential new approach to treating immune-mediated diseases.

Transcenta's osemitamab (TST001) demonstrated a median PFS of 12.6 months in G/GEJ cancer patients with high/medium Claudin18.2 expression when combined with checkpoint inhibitors and CAPOX.

Nxera Pharma received $35 million from Neurocrine Biosciences following positive Phase II trial results of NBI-1117568 in adults with schizophrenia.

The PALIZADE trial is a Phase 2b study assessing zetomipzomib (KZR-616) for treating active lupus nephritis, a severe complication of systemic lupus erythematosus.

A randomized trial, SELECT-AV, compared self-expandable (SE) and balloon-expandable (BE) valves in transcatheter aortic valve replacement (TAVR).

RGX-121 gene therapy demonstrates an 85% median reduction in cerebrospinal fluid levels of heparan sulfate D2S6, a key biomarker in Hunter syndrome.

The FDA has granted orphan drug designation to certepetide for the treatment of cholangiocarcinoma, a rare and aggressive cancer with limited treatment options.

Femasys Inc. has received FDA 510(k) clearance for FemChec, a diagnostic solution designed for checking the fallopian tubes using controlled contrast delivery.

A phase 2 trial reveals ruxolitinib's effectiveness in treating refractory sclerotic chronic graft-versus-host disease (cGVHD), particularly affecting the skin and joints.

Bayer's BAY 2927088 demonstrated a 72.1% objective response rate in HER2-mutant NSCLC patients in an early to mid-stage study.

PainReform's PRF-110, a non-opioid post-surgical pain relief solution, demonstrates compatibility with both non-absorbable and resorbable sutures in human clinical trials.